The independent medical news service
21-10-2021 | Oncology | News | Article
Hearing loss protection recommendations made for paediatric CNS, head and neck cancer patients
The risk of high-frequency hearing loss in children undergoing cancer treatment to the central nervous system or the head and neck could be reduced by minimising doses of radiation to the cochlea and limiting cumulative doses of cisplatin or carboplatin, Canadian researchers say.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
24-10-2018 | Head and neck cancer | Video
De-ESCALaTE HPV results revealed
Hisham Mehanna describes the results of the De-ESCALaTE HPV trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).
Pills in hand/© stock_colors / Getty Images / iStock, Male & female outlines_chalk/© TimArbaev / iStock / Thinkstock, Hisham Mehanna/© Lynda Williams